Debanjana Chatterjee
Stock Analyst at JonesTrading
(4.93)
# 210
Out of 4,696 analysts
254
Total ratings
63.2%
Success rate
39.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Maintained: Buy | $26 | $17.24 | +50.81% | 12 | Sep 2, 2026 | |
| ATHE Alterity Therapeutics | Maintained: Buy | $16 | $4.52 | +253.98% | 4 | Aug 28, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $10 | $4.45 | +124.72% | 23 | Aug 28, 2026 | |
| ARMP Armata Pharmaceuticals | Maintained: Buy | $20 | $5.53 | +261.66% | 6 | Aug 28, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $52 | $35.17 | +47.85% | 14 | Aug 28, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $140 → $121 | $87.05 | +39.00% | 20 | Aug 26, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $31 | $10.99 | +182.07% | 18 | Aug 25, 2026 | |
| EVAX Evaxion | Maintained: Buy | $10 | $3.07 | +225.73% | 4 | Aug 21, 2026 | |
| EYPT EyePoint | Maintained: Buy | $43 → $20 | $4.79 | +317.54% | 28 | Aug 18, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $29 | $12.76 | +127.27% | 28 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $24 → $28 | $17.05 | +64.22% | 22 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $8.80 | +47.73% | 19 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.88 | +538.30% | 17 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $25 | $11.36 | +120.07% | 8 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $7.31 | +761.83% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.34 | +274.53% | 2 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $19 → $17 | $17.07 | -0.41% | 12 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.02 | - | 8 | May 22, 2026 |
Contineum Therapeutics
Sep 2, 2026
Maintained: Buy
Price Target: $26
Current: $17.24
Upside: +50.81%
Alterity Therapeutics
Aug 28, 2026
Maintained: Buy
Price Target: $16
Current: $4.52
Upside: +253.98%
Opus Genetics
Aug 28, 2026
Maintained: Buy
Price Target: $10
Current: $4.45
Upside: +124.72%
Armata Pharmaceuticals
Aug 28, 2026
Maintained: Buy
Price Target: $20
Current: $5.53
Upside: +261.66%
Pharvaris
Aug 28, 2026
Maintained: Buy
Price Target: $52
Current: $35.17
Upside: +47.85%
Spyre Therapeutics
Aug 26, 2026
Reiterated: Buy
Price Target: $140 → $121
Current: $87.05
Upside: +39.00%
Sagimet Biosciences
Aug 25, 2026
Reiterated: Buy
Price Target: $31
Current: $10.99
Upside: +182.07%
Evaxion
Aug 21, 2026
Maintained: Buy
Price Target: $10
Current: $3.07
Upside: +225.73%
EyePoint
Aug 18, 2026
Maintained: Buy
Price Target: $43 → $20
Current: $4.79
Upside: +317.54%
Intellia Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $29
Current: $12.76
Upside: +127.27%
Aug 13, 2026
Rated: Buy
Price Target: $24 → $28
Current: $17.05
Upside: +64.22%
Aug 12, 2026
Maintained: Buy
Price Target: $13
Current: $8.80
Upside: +47.73%
Aug 10, 2026
Maintained: Buy
Price Target: $12
Current: $1.88
Upside: +538.30%
Aug 10, 2026
Reiterated: Buy
Price Target: $13 → $25
Current: $11.36
Upside: +120.07%
Aug 10, 2026
Downgraded: Hold
Price Target: $63
Current: $7.31
Upside: +761.83%
Jul 23, 2026
Maintained: Buy
Price Target: $5
Current: $1.34
Upside: +274.53%
Jun 29, 2026
Downgraded: Hold
Price Target: $19 → $17
Current: $17.07
Upside: -0.41%
May 22, 2026
Rated: Hold
Price Target: n/a
Current: $0.02
Upside: -